



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 5/00, 15/63, 1/21, 15/64</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/39411</b> <b>(43) International Publication Date:</b> 11 September 1998 (11.09.98)
<b>(21) International Application Number:</b> PCT/US98/03473 <b>(22) International Filing Date:</b> 23 February 1998 (23.02.98)  <b>(30) Priority Data:</b> 08/810,039                      4 March 1997 (04.03.97)                      US  <b>(71) Applicant:</b> BAXTER INTERNATIONAL INC. [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US).  <b>(72) Inventors:</b> AYARES, David; 186 HighPoint Drive, Lindenhurst, IL 60046 (US). ALEMANY, Ramon; 1904 Country Drive #204, Grayslake, IL 60030 (US). ZHANG, Wei-Wei; 1915 Darnell Street, Libertyville, IL 60048 (US).  <b>(74) Agents:</b> BATES, Sarah, E. et al.; Baxter Healthcare Corporation, Route 120 & Wilson Road, Round Lake, IL 60073 (US).	<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> ADENOVIRUS E1-COMPLEMENTING CELL LINES		
<b>(57) Abstract</b>		
<p>A new series of helper cell lines for the complementation, amplification, and controlled attenuation of E1-deleted adenovirus are disclosed in the present invention. These cell lines are advantageous because they can complement adenovirus E1 gene deletions without production of replication competent adenovirus (RCA), thus making them safer for the large-scale production of adenovirus stock for use in human gene therapy trials. A preferred embodiment is an A549E1 cell line that contains only the Ad5 E1 DNA sequences sufficient for complementation of E1-deleted adenoviral vectors without sequences that overlap with the adenovirus vector. In another aspect, the present invention embodies methods for the production of second generation A549-E1 complementing cell lines that, in addition to producing E1, also produce proteins required for further manipulation of adenoviral vectors. A preferred embodiment is an A549E1 cell line with DNA sequences that encode a polypeptide sufficient for packaging attenuation of E1-deleted helper virus, in order to enrich for packaging of mini-adenovirus.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ADENOVIRUS E1-COMPLEMENTING CELL LINES

### FIELD OF THE INVENTION

This invention relates to novel cells and methods for use in propagating E1-  
5 deleted adenoviruses.

### CROSS-REFERENCE

This application is a continuation-in-part of serial number 08/658,961 filed May  
31, 1996.

### BACKGROUND OF THE INVENTION

10 The majority of adenoviral vectors used in gene therapy applications were  
designed to have deletions in the E1 region of the adenovirus 5 (Ad5) genome. The E1  
region, not including region IX, consists of 9% of the left end of Ad5 (1.2 - 9.8 map  
units), and is subdivided into two regions, E1A and E1B, each one coding for several  
proteins. Expression of E1A/E1B is required for virus replication and for expression of  
15 all other Ad5 proteins (E2-E4, Late Proteins; Ginsberg, H.S. The Adenoviruses. Plenum  
Press, New York. p.46-67(1984). Deletion of E1, therefore creates a replication-  
incompetent virus that, in theory, is silent for expression of all Ad5 proteins and  
expresses only the transgene of interest. Deletion of E1A and E1B is also of interest for  
safety reasons, since these two proteins, in combination, have been implicated in  
20 oncogenic transformation of mammalian cells (Graham, et al., In *Cold Spring Harbor  
Symp. Quant. Biol.* 39, p. 637-650 (1974); Van Der Eb, et al., *Gene* 2, p.115-132 (1977);  
McKinnon, et al., *Gene* 19, p. 33-42(1982). All of the Class I adenovirus vectors used to  
date in human clinical trials, are deleted for E1.

E1 deficient adenoviral vectors are propagated in an Ad5 helper cell line called

293 (Graham, F.L. and Smiley, J, *J. Gen. Virol.* 36, p.54-72 (1977). 293 cells were derived by transforming human embryonic kidney cells with sheared fragments of Ad5 DNA. Genomic analysis revealed that 293 cells contain four to five copies per cell of the left 12% of the viral genome (including the entire E1 region) and approximately one copy  
5 per cell of 9% of the right end, the E4 region (Aiello,L.,et al, *Virology* 94, p.460-469 (1979). While 293 cells are very efficient at producing high titers of E1-deficient adenovirus, they have the disadvantage that, due to the presence of Ad5 sequences besides E1 integrated into the 293 genome, recombination can occur with sequences in the E1-deficient adenovirus vector causing the production of E1-containing, replication-  
10 competent adenovirus (RCA). Depending on how early a passage the aberrant recombination event occurs during the amplification and propagation of the E1-deficient adenovirus, and which passage is used for large-scale production of the adenovirus stock, production of RCA in 293 cells can present severe ramifications for the safety of human gene therapy trials (Lochmuller, H., et al., *Human Gene Therapy* 5, p. 1485-1491 (1994).  
15 In addition to production of RCA, recombination in 293 cells can also cause deletions and rearrangements that affect transgene expression, thereby decreasing the titer of functional adenovirus particles. Recently, cell lines have been developed using defined Ad5 DNA fragments, including the E1 region; however these cell lines contain significant sequence overlap with homologous sequences in the E1-deleted adenovirus vectors, thus allowing  
20 for undesirable homologous recombination events and the possibility for generation of RCA (Fallaux, et al., *Human Gene Therapy* 7, p. 215-222 (1996); Imler, et al., *Gene Therapy* 3, p. 75-84 (1996).

In this invention, a series of cell lines have been generated containing only the

minimal E1 gene region for the complementation of E1-deleted adenoviral vectors, in the absence of RCA.

### **SUMMARY OF THE INVENTION**

5           This invention encompasses a series of helper cell lines for the complementation, amplification, and controlled attenuation of E1-deleted adenovirus. These cell lines are advantageous because they can complement adenovirus E1 gene deletions without production of replication competent adenovirus (RCA). A preferred embodiment is an A549E1 cell line that contains only the Ad5 E1 DNA sequences sufficient for  
10   complementation of E1-deleted adenoviral vectors without sequences that overlap with the adenovirus vector. In a preferred embodiment, the E1 DNA sequences comprise E1A and E1B genes.

          In another aspect, the present invention embodies methods for selectively propagating mini-adenovirus without generating RCA, by transfecting an A549E1 cell  
15   line with DNA sequences that encode a polypeptide sufficient for packaging attenuation of E1-deleted helper virus. In a preferred embodiment, the polypeptide comprises Cre recombinase. In another preferred embodiment, the polypeptide comprises TetR-KRAB.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

20   **Figure 1** is a diagram indicating the structure of adenovirus sequences in a typical E1-deleted Ad helper virus (top line), in 293 cells (ref.5), and in other E1-containing cell lines, including 911 cells (ref.8) and A549E1-68 cells (this invention); and how recombination between homologous adenovirus sequences occurs to generate a

replication-competent adenovirus (RCA).

**Figure 2** is a diagram of the CMV-E1 mammalian expression vector.

**Figure 3** is a Southern blot analysis of G418<sup>r</sup> A549E1 clones.

**Figure 4A** is a Western blot analysis of E1A protein expression in A549 cells, 293 Cells,  
5 and A549E1-68.

**Figure 4B** is the metabolic <sup>35</sup>S labeling and immunoprecipitation of E1B proteins in A549 Cells, 293 Cells and 4 single-cell clones derived from A549E1-68.

**Figure 5** is a representation of the E1-deleted adenovirus vector, Ad5-CA-GFP.

**Figure 6** is an agarose gel analysis of 40 PCR reactions using E1A-specific primers for  
10 detection of RCA.

**Figure 7** is a diagram of a system for the attenuation of helper virus with a loxP-modified packaging signal.

**Figure 8** is a diagram of the pCMV-Cre-Puro vector.

**Figure 9** is a diagram of the pBS/loxP-stop/MCLpA vector.

15 **Figure 10** is a bar graph depicting luciferase expression in both control cells (A549E1-68) and cell lines expressing the TetR-KRAB protein, following transient transfection with the pTetO7-CMV-L test vector.

### **DETAILED DESCRIPTION OF THE INVENTION**

20 This invention provides cell lines that can complement E1-deleted adenovirus without the disadvantage of undesirable recombination and RCA. These cell lines are obtained by cloning and expressing in the A549 cell line only those sequences that are required for E1 complementation and excluding from the cell line all other Ad5

sequences that have homology to the vector and could cause recombination to produce RCA.

Currently 293 cells are used to propagate E1-deleted adenovirus. However, 293 cells harbor DNA fragments that make up 21 % of the Ad5 genome. 293 cells therefore have significant sequence homology (outside of the E1 region) that overlaps with sequences in the adenoviral vectors, which can allow for homologous recombination events to produce a wild type adenoviral particle. **FIG. 1** shows the structure of adenovirus sequences in 293 cells versus other E1-containing cell lines (including A549E1 cells), and how recombination between homologous adenovirus sequences occurs to generate a replication-competent adenovirus (RCA). Significant homology (more than 1000 base pairs) exists between Ad sequences 3' to the E1 region in conventional adenovirus vectors, and sequences integrated into the helper cell genome of 293 cells and 911 cells. Reciprocal recombination across these homologous regions can result in the generation of a wild-type, E1(+), replication-competent adenovirus (RCA).

This invention embodies the cloning of an E1A and E1B-encoding DNA fragment from Ad5 into a mammalian expression vector. This E1 vector was stably transfected into human A549 cells to produce an E1 expression cell line. The genome of a representative cell line, A549E1-68, contains no sequence overlap with sequences present in the E1-deleted Ad helper virus and thus, recombination to produce RCA is not possible (**FIG. 1**). Characterization of this A549E1 cell line demonstrated the production of E1A and E1B proteins, high infectivity with adenovirus vectors, complementation of E1-deleted adenovirus to produce high-titer virus stocks, as well as, the lack of production of replication-competent adenovirus (RCA).

Further embodiments of the invention are described for the production of 2nd generation A549-E1 complementing cell lines which, in addition to producing E1, also produce proteins required for further manipulation of adenoviral vectors, thus providing a novel series of RCA-free adenovirus helper cell lines, as tools for novel virus production.

5 The first example is an A549E1 cell line which expresses the Cre recombinase. This invention provides a novel E1-deleted helper virus whose packaging signal is flanked by loxP sites, and when this helper virus is propagated in an A549E1 cell line expressing Cre, the packaging signal is deleted by excision, thus attenuating helper virus packaging and enriching for packaging of mini-adenovirus (Ad5 virus which is devoid of all viral  
10 protein-coding sequences). This is advantageous because during the production of helper-dependent, mini-adenovirus it becomes necessary to attenuate helper virus packaging in order to enrich for the mini-virus. 293-Cre cells have been generated for this purpose (Parks, R. , et al., *P.N.A.S.* 93, p.13565-13570 (1996), however, A549E1-Cre cells have an advantage in that they would perform this task in an RCA-free  
15 environment.

A further embodiment of the present invention includes an A549-E1 complementing cell line which expresses the TetR-KRAB fusion protein, which would be used to amplify, and control the packaging efficiency of an E1-deleted helper virus whose packaging signal has been modified to contain multiple tetracycline operator (tetO) sites.  
20 When this helper virus is propagated in an A549E1 cell line expressing TetR-KRAB, the repressor binds to the tetO sequence and specifically attenuates helper virus packaging, thus enriching for packaging of the mini-adenovirus which has a normal, wild-type packaging signal. Packaging of the helper virus can be restored by growing the cells and



virus in the presence of tetracycline, which binds to the tet-KRAB repressor causing its dissociation from the tetO/packaging signal and a reversal of packaging repression. Detailed examples involving the derivation, characterization, and applications of these E1-complementing helper cell lines are described in the following sections.

5

### **Example 1**

#### ***Construction of the E1A/E1B vector***

To generate an expression vector which harbors only the E1A/E1B sequences required for complementation, a 3.1 kb DNA fragment coding for Ad5 E1A and E1B  
10 genes was cloned in two pieces, sequentially, into the superlinker vector, pSL301 (Invitrogen). First, an 881 bp Afl III to XbaI fragment (Ad5 base pairs 462-1343) was cloned from pBRXad5KpnIC1 (a subclone of pJM17) into pSL301 (Afl III/XbaI). Second, a contiguous 2194 bp XbaI to Afl II (Ad5 base pairs 1343-3537) was cloned from pBRXad5XhoIC1 into the same vector. The resultant 3075 bp E1 fragment (in  
15 pSL301) contains the TATA box and RNA cap site for E1A, E1A coding sequence, complete E1B promoter, and E1B coding sequence, including the stop codon for E1B p55 protein, but not including region IX. The 3075 bp Afl III - Afl II E1A/E1B fragment (Ad5 base pairs 462-3537) was isolated, blunt-ended with Klenow enzyme, and blunt-end ligated into the EcoRV site of the mammalian expression vector, pCDNA3 (Invitrogen),  
20 under control of the CMV promoter/enhancer. This process generated an Ad5-E1 expression vector, pCMV-E1 (**FIG.2**).

## **Example 2**

### ***Generation and characterization of the E1 cell line***

This CMV-E1 expression plasmid, (FIG. 2), was transfected using Lipofectamine (Gibco/BRL) into A549 human lung carcinoma cells (ATCC CRL 185) and G418<sup>R</sup> colonies were isolated. Single-cell clones were screened for functional E1A/E1B expression. An E1-deleted adenovirus containing a green fluorescence protein (GFP) expression cassette, Ad5 CA-GFP, was used to infect the A549-E1 clones. Three days post-infection, clones were screened for production of E1-complemented Ad5 CA-GFP adenovirus by visual examination for cytopathic effect (CPE). One clone, A549E1-68, displayed 100% CPE in 3 days, similar to that observed for 293 cells. The clear area in the center of the plaque is evidence of CPE caused by E1-complemented virus amplification. This clone also showed high infectivity, in that virtually 100% of the cells fluoresced green 24 hours post-infection. The high infection rate and rapid generation of CPE induced in this cell line is strong evidence that functional E1A/E1B proteins are being produced that are capable of promoting replication and amplification of the E1-deleted Ad5-CA-GFP virus. The A459E1 cell was deposited at the American Type Tissue Culture Collection (ATCC) under the Budapest Treaty on January 15, 1998 as ATCC Designation CRL-12458 (viability confirmed January 20, 1998).

FIG. 3 shows a Southern blot using an E1 sequence-specific DNA probe. This assay demonstrated the presence of the CMV-E1 transgene in A549E1-68 (Lane 4), and a subclone of A549E1-68 (E1-68.3), but not in the parental A549 cell line (Lane 2). Sequences hybridizing with the E1-specific probe were also observed in 293 cells as expected since they complement E1-deleted adenovirus (Lane 3). The morphology of the

E1-transfected cells was significantly different from the parental A549 cell line. A549 cells at sub-confluent density grow as distinct single cells with an elongated, fibroblast-like morphology, whereas the E1 cell line A549E1-68 grows as colonies of cells with a more cuboidal morphology. A549E1-68 was also compared with 293 cells for production of E1-deleted adenovirus (Ad5 CA-GFP) by plaque assay and found to produce an equivalent titer of complemented virus ( $7 \times 10^9$  pfu for A549E1-68 vs.  $9 \times 10^9$  pfu for 293).

**FIG. 4A** shows a Western blot analysis using an E1A specific antibody (M73, Oncogene Science). This antibody detected two E1A-specific bands with apparent molecular weights of 46kd and 42kd in the A549E1-68 cell line (lane 3), corresponding to products expected from E1A 13S and 12S mRNAs (Ginsberg, 1984), and identical in size to those observed in 293 cells (lane 2). These E1A-specific bands were not detected in parental A549 cells (lane 1). **FIG. 4B** shows the immunoprecipitation of metabolically-radiolabeled proteins by a monoclonal antibody specific for E1B p55. A549E1-68 produced an immunoreactive band of approximately 55 kd (lane 3) that was not detected in parental A549 cells. This 55 kd, E1B-specific band, as well as secondary background bands, were observed in 293 cells also (lane 2). Extra "background" bands found in both experimental and control lanes have been observed by other authors and are attributed to co-immunoprecipitation of a variety of proteins including, cyclins, p53, and Rb. It is clear that A549E1-68 not only expresses E1A and E1B, but that they are functional, since this cell line can complement for production of high titer, E1-deleted, recombinant adenovirus.

### Example 3

#### *E1-deleted adenovirus produced in A549E1 cells is RCA-free*

To prove that this new Ad5 helper cell line can complement without production of RCA, a series of PCR RCA assays were performed following amplification in A549E1 cells of the E1-deleted Ad5-CA-GFP adenovirus vector. The Ad5-CA-GFP vector is illustrated in **FIG. 5**. It contains a transcriptional control element consisting of the CMV enhancer and the  $\beta$ -actin promoter and the deletion of E1 sequences includes a lack of Ad5 DNA through base pair 3550. Since the E1A/E1B complementing region contained in the A549E1 cells extends only to base pair 3537, there is no overlapping sequence homology to allow RCA production. E1-deleted vectors with smaller deletions may still contain some E1 DNA and should be avoided, as they could still allow RCA to occur at a low frequency.

For the PCR RCA assay, Ad5-CA-GFP virus was serially propagated through 20 passages on A549E1-68 cells. Following serial propagation and virus amplification, Ad5-CA-GFP virus DNA was isolated by freeze-thaw lysis, and PCR was performed using primers specific for either the E1A region or the E2B region. Amplification of an 880 bp E2B product serves as a PCR positive control, while the presence of a 1086 bp E1A-specific product is evidence that an E1 (+) replication-competent adenovirus (RCA) has been produced during amplification of the E1 (-) Ad5-CA-GFP. 20 ug of Ad5-CA-GFP virus DNA (equivalent to  $1 \times 10^{10}$  virus particles), obtained from amplification in A549E1 cells, was divided into 40 PCR reactions and tested for RCA using the E1A primers (**FIG. 6**). For both top and bottom panels of **FIG. 6**, lane 1 contains 1 kb DNA markers, lane 2 contains wild type Ad5 virus DNA, lane 3 consists of PCR of Ad5-CA-

GFP virus DNA (E1-) isolated from 20+ passages on A549E1-68 cells using E1A and E2B specific primers (positive control), and lanes 4-20 consist of PCR of Ad5-CA-GFP virus DNA (E1-) isolated from 20+ passages on A549E1-68 cells, using E1A-specific primers only. No 1086 bp E1 region specific PCR fragments were detected in any of the reactions indicating that no RCA was present in the virus prep.

A second, CPE-based RCA assay was performed by amplifying E1-deleted adenovirus (Ad5-CA-GFP) on A549E1-68 cells and testing the amplified virus by passaging, on normal A549 cells (don't make E1) for production of E1-containing RCA. Plaque formation (CPE) on a monolayer of normal A549 cells would provide evidence for the production of wild-type (E1 +) virus during amplification on the E1 helper cell line, A549E1-68.  $2 \times 10^{10}$  E1 (-) virus particles (amplified using A549E1-68) were used to infect each of five 150mm plates of normal A549 cells ( $1 \times 10^{11}$  particles total). No CPE or single plaques were detected after 8 days on any of the A549 plates, indicating the absence of any E1 (+) RCA virus in the A549E1-68-amplified virus prep. Therefore, using two sensitive assays for detection of RCA, no wild-type recombinant E1 (+) virus was detected, supporting the utility of this cell line for the amplification and large-scale preparation of E1-deleted adenoviral vectors in the absence of RCA.

#### **Example 4**

##### ***Generation of an A549E1 Cre Cell Line***

A 2nd generation E1-complementing cell line was generated using the A549E1-68.3 clonal line for transfection with Cre recombinase. This cell line will both complement E1-deleted adenovirus vectors and mediate the excision of sequences

surrounded by loxP sites. Our primary use for this cell line is to further attenuate packaging of an Ad5 helper virus, whose packaging signal is flanked by two loxP sites (FIG. 7), in order to enrich for packaging of the desired E1-deficient, mini-adenovirus vector. 293 cells expressing the Cre recombinase were generated for a similar purpose by Parks et al. (P.N.A.S. 93:13565-13570), and were shown to increase the titer of E1-deleted vector virus 10 fold per passage, demonstrating the overall utility of this system for removal of helper virus. The A549E1-Cre cell line described in this invention will not only attenuate helper virus packaging in a similar fashion, it also has the advantage that any adenovirus produced will be free of deleterious RCA.

10 As a first step towards the production of the A549E1-Cre cell line, a Cre expression vector was constructed. A 1440 bp SV40 promoter-puromycin cassette (for selection in Neo<sup>R</sup> A549E1 cells) was cloned into a unique EcoRI site of the CMV-Cre vector (pBS185, Gibco/BRL) to generate pCMV-Cre-Puro (FIG. 8). The pCMV-Cre-Puro vector was transfected by electroporation into A549E1-68 cells, and puromycin<sup>R</sup> 15 ("puro<sup>R</sup>") clones were isolated. These puro<sup>R</sup> clones were then screened for expression of functional Cre recombinase. The plasmid pBS/loxP-stop/MCLpA contains a lacZ cassette that is non-functional due to the presence of a stop codon (FIG. 9). This stop codon is surrounded by loxP sites, such that the propagation of this vector in a cell line producing Cre would excise the stop signal and activate the lacZ gene. The pBS/loxP- 20 stop/MCLpA vector was transiently transfected into each of the A549E1-Cre clones, and after 24 hours. the transfected cells were fixed and stained with X-Gal. LacZ expression of parental A549E1-68 cells (no Cre) was compared to lacZ expression in seven different puro<sup>-</sup> A549E1-Cre clones. Expression of lacZ (due to expression of Cre) was observed as

blue cells, at a frequency ranging from 1% to 50% in 20/26 puro<sup>R</sup> clones. This range of LacZ-expressing cells is most likely a reflection of the transient transfection efficiency of the different puro<sup>R</sup> clones with the pBS/loxPstop-MCLpA vector, although it could also reflect variations in Cre recombinase expression in different cell lines. Western blot  
5 analysis using an anti-Cre antibody (Pharmingen), confirmed the presence of the 35 kd Cre protein in these cell lines. Experiments to assess the attenuation of Ad helper virus containing a packaging signal flanked by two loxP sites are in progress.

### Example 5

#### 10 *Generation of an A549E1 cell line expressing TetR-KRAB*

A highly conserved, 75 amino acid protein called the Kruppel-associated box (KRAB) was recently isolated by Margolin, et al. (*P.N.A.S.* 91, p.4509-4513 (1994)). The KRAB box is a member of the Kox-1 family of human zinc finger proteins and was subsequently shown to be a strong transcriptional repressor. By fusing the KRAB  
15 domain from Kox-1 to the Tet repressor derived from Tn10 of *Escherichia coli*, a hybrid protein was generated, TetR-KRAB, which allows tetracycline-controlled silencing of eukaryotic promoters (Deuschle, et al., *Mol. and Cell. Biol.* 15, p.1907-1914 (1995)). The TetR-KRAB repressor binds to tetO sequences present in a transcriptional control region and represses transcription of genes placed as far as 3 kb downstream.

20 The present invention describes a system for tetracycline-controlled inhibition of helper virus packaging, comprising multiple tetO sequence in the helper virus packaging signal sequence, and an E1 helper cell line that constitutively expresses the TetR-KRAB protein. The helper virus is still capable of replicating and providing all the necessary

proteins, *in trans*, required for replication of the miniAd vector, however, its packaging is attenuated due to binding of the TetR-KRAB protein to the tetO sites in the packaging signal. The overall goal is to hinder or repress helper virus packaging, thus enriching for vector virus packaging. This packaging repression is reversible, since in the presence of  
5 tetracycline, the TetR-KRAB repressor dissociates from the tetO sequences, and packaging is restored. Details of this tetO-controlled helper virus were presented in an earlier patent application (Serial No. 08/658,961, filed May 31, 1996).

The TetR-KRAB expressing cell line was derived using the A549E1-68 helper cell line described in Example 2. A549E1-68 cells were transfected with a TetR-KRAB  
10 gene under control of the CMV promoter (see Deuschle et al., *Mol. Cell. Biol.* 15 p. 1907-1914 (1995)). The TetR-KRAB vector also contains a hygromycin resistance gene for selection in mammalian cells. A test vector (see Deuschle, et al., *Mol. and Cell. Biol.* 15 p.1907-1914 (1995)) that has a luciferase reporter gene under control of the CMV promoter fused to a TetO sequence was used for transient transfection into cells lacking a  
15 TetR-KRAB repressor. This transfection results in high level expression of luciferase, whereas transfection into A549E1 cells expressing the TetR-KRAB protein will result in the repression of luciferase due to binding of the repressor to tetO sites in the test vector. Hygromycin-resistant A549E1-TetR-KRAB clones were transfected with pTetO-CMV-L by electroporation and each clone was split into two wells of a 6-well plate. 24 hours  
20 post-transfection, cells from one duplicate well were refed with medium containing tetracycline, and the other duplicate well in medium without tetracycline. After another 24 hours, cells were lysed and assayed for luciferase expression using a Promega Luciferase Assay Kit. Two hygro<sup>R</sup> A549E1 clones (TKE-9 and TKE-12) demonstrated a



4 to 6 fold repression of luciferase reporter activity when grown in the absence of tetracycline versus cells grown in media containing Tet, indicating expression of the TetR-KRAB repressor protein in the cells (FIG. 10). These A549E1-TetR-KRAB cell lines will be used to test attenuation of the TetO-controlled Ad helper virus.

- 5           These examples are intended to illustrate the present invention and are not intended to limit it in spirit or scope.

**CLAIMS****WE CLAIM:**

1. A recombinant cell, comprising a mammalian cell capable of expressing a region of the adenoviral E1 sequence sufficient for complementation of E1-deleted  
5 adenoviral vectors without generating replication-competent adenovirus.
2. The recombinant cell of claim 1 further comprising said mammalian cell capable of expressing DNA sequences that encode a polypeptide sufficient for attenuation control of E1-deleted helper virus.
3. The recombinant cell of claim 2 wherein said DNA sequences comprise a Cre  
10 recombinase-encoding DNA.
4. The recombinant cell of claim 2 wherein said DNA sequences comprise a TetR-KRAB-encoding DNA.
5. A method for propagating E1-deleted adenovirus without generating replication-competent adenovirus comprising:  
15 (a) transfecting a mammalian cell with a region of the adenoviral E1 sequence sufficient for complementation of said E1-deleted adenovirus without generating replication-competent adenovirus;  
(b) infecting said mammalian cells with said E1-deleted adenovirus; and  
(c) growing said mammalian cells under conditions suitable for lysis of said  
20 mammalian cells by said complementation of E1-deleted adenovirus.
6. A method of selectively propagating mini-adenovirus without generating replication-competent adenovirus comprising:  
(a) transfecting a mammalian cell with a region of the adenoviral E1 sequence

sufficient for complementation of said E1-deleted adenovirus without generating replication-competent adenovirus;

- (b) further transfecting said mammalian cell with DNA sequences that encode a polypeptide sufficient for attenuation control of E1-deleted helper virus;
- 5 (c) co-infecting said mammalian cells with said E1-deleted helper virus, said E1-deleted helper virus containing a modified packaging signal that is controlled by said polypeptide;
- (d) growing said mammalian cells under conditions sufficient for lysis of said mammalian cells by said complementation of E1-deleted adenovirus; and for  
10 said attenuation control of said E1-deleted helper virus.

7. The method of claim 6, wherein

- (a) said DNA sequences that encode a polypeptide sufficient for attenuation control of E1-deleted helper virus comprise a Cre recombinase-encoding DNA; and
- 15 (b) said modified packaging signal that is controlled by said polypeptide sufficient for attenuation of E1-deleted helper virus comprises loxP sites adjacent to said packaging signal.

8. The method of claim 6, wherein

- (a) said DNA sequences that encode a polypeptide sufficient for attenuation  
20 control of E1-deleted helper virus comprise a TetR-KRAB-encoding DNA;  
and
- (b) said modified packaging signal that is controlled by said protein for attenuation of E1-deleted helper virus comprises a tetO DNA sequence in

said modified packaging signal.

9. A method for making a recombinant cell comprising:
  - (a) transfecting a mammalian cell with a region of the adenoviral E1 sequence sufficient for complementation of E1-deleted adenoviral vectors without  
5 generating replication-competent adenovirus; and
  - (b) selecting for recombinant cells that express said region of the adenoviral E1 gene.
10. A method for using a recombinant mammalian cell capable of expressing a region of the adenoviral E1 gene sufficient for complementation of E1-deleted  
10 adenovirus without generating replication-competent adenovirus, comprising:
  - (a) infecting said recombinant mammalian cells with said E1-deleted adenovirus; and
  - (b) growing said mammalian cells under conditions sufficient for lysis of said mammalian cells by said complementation of E1-deleted adenovirus and  
15 propagation of said E1-deleted adenovirus.
11. The method of claim 10 wherein said recombinant mammalian cell is a human cell.
12. The method of claim 10 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.
- 20 13. The method of claim 10 wherein said recombinant mammalian cell is deposited with the ATCC under accession number CRL-12458.
14. A method of using a recombinant cell, comprising a mammalian cell capable of expressing adenoviral E1A and E1B sequences sufficient for complementation of

E1-deleted adenovirus without generating replication-competent adenovirus, comprising:

- (a) infecting said recombinant mammalian cells with said E1-deleted adenovirus; and
  - 5 (b) growing said mammalian cells under conditions sufficient for lysis of said mammalian cells by said complementation of E1-deleted adenovirus and propagation of said E1-deleted adenovirus.
15. The method of claim 14 wherein said recombinant mammalian cell is a human cell.
- 10 16. The method of claim 14 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.
17. The method of claim 14 wherein said recombinant mammalian cell is deposited with the ATCC under accession number CRL-12458.
18. A method for using a recombinant mammalian cell capable of expressing a region  
15 of the adenoviral E1 gene sufficient for complementation of E1-deleted helper virus without generating replication-competent adenovirus and also capable of expressing DNA sequences that encode a protein for attenuation control of said E1-deleted helper virus, comprising:
- (a) co-infecting said mammalian cells with an E1-deleted helper virus, said E1-  
20 deleted helper virus containing a modified packaging signal that is controlled by said protein for attenuation of E1-deleted adenovirus, and a mini-adenovirus; and


(b) growing said mammalian cells under conditions sufficient for lysis of said mammalian cells by said complementation of E1-deleted adenovirus and also sufficient for said attenuation control of said E1-deleted helper virus.


19. The method of claim 18 wherein said recombinant mammalian cell is a human  
5 cell.
20. The method of claim 18 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.
21. The method of claim 18 wherein said DNA sequences comprise a Cre recombinase-encoding DNA that encodes a polypeptide sufficient for said  
10 attenuation control of E1-deleted adenovirus.
22. The method of claim 18 wherein said recombinant mammalian cell is a human cell.
23. The method of claim 18 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.
- 15 24. The method of claim 18 wherein said recombinant mammalian cell is deposited with the ATCC under accession number CRL-12458.
25. The method of claim 18 wherein said DNA sequences comprise a TetR-KRAB-encoding DNA that encodes a polypeptide sufficient for said attenuation control of E1-deleted adenovirus.
- 20 26. The method of claim 25 wherein said recombinant mammalian cell is a human cell.
27. The method of claim 25 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.

28. The method of claim 25 wherein said recombinant mammalian cell is deposited with the ATCC under accession number CRL-12458.
29. A method for using a recombinant mammalian cell capable of expressing adenoviral E1A and E1B sequences sufficient for complementation of E1-deleted helper virus without generating replication-competent adenovirus and also capable of expressing a protein for controlling attenuation of said E1-deleted helper virus, comprising :
- 5 (a) co-infecting said mammalian cells with an E1-deleted helper virus, said E1-deleted helper virus containing a modified packaging signal that is controlled by said protein for attenuation of E1-deleted adenovirus, and a mini-adenovirus; and
- 10 (b) growing said mammalian cells under conditions sufficient for lysis of said mammalian cells by said complementation of E1-deleted adenovirus and also sufficient for said attenuation control of said E1-deleted helper virus.
- 15 30. The method of claim 29 wherein said recombinant mammalian cell is a human cell.
31. The method of claim 29 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.
32. The method of claim 29 wherein said DNA sequences comprise a Cre recombinase-encoding DNA that encodes a polypeptide sufficient for said attenuation control of E1-deleted adenovirus.
- 20 33. The method of claim 32 wherein said recombinant mammalian cell is a human cell.

34. The method of claim 32 wherein said recombinant mammalian cell is A549 human lung carcinoma cell.
35. A method of claim 32 wherein said recombinant mammalian cell is deposited with the ATCC under accession number CRL-12458.
- 5 36. A method of claim 29 wherein said DNA sequences comprise a TetR-KRAB-encoding DNA that encodes a polypeptide sufficient for said attenuation control of E1-deleted adenovirus.
37. A method of claim 36 wherein said recombinant mammalian cell is a human cell.
38. A method of claim 36 wherein said recombinant mammalian cell is A549 human  
10 lung carcinoma cell.
39. The method of claim 38 wherein said recombinant mammalian cell is deposited with the ATCC under accession number CRL-12458.






**FIGURE 2**

**FIGURE 3**


**1 2 3 4**




**- 3.0 kb**

4/10


**FIGURE 4A**




**FIGURE 4B**




**FIGURE 5**  
**Ad5-CA-GFP (E1-deleted)**



**FIGURE 6**



**FIGURE 7****LoxP-Attenuated Ad5 Helper Virus**



**FIGURE 8**



FIGURE 9



10/10




FIGURE 10

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/03473

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>														
IPC(6) : C12N 5/00, 15/63, 1/21, 15/64 US CL : 435/325, 320.1, 69.1, 91.4 According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b>														
Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/325, 320.1, 69.1, 91.4														
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE														
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, CAS ONLINE, MEDLINE														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	FALLAUX et al. Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors. Human Gene Therapy. 20 January 1996, Vol. 7, pages 215-222, especially pages 221.	1-5												
Y	WO 95/34671 A1 (GENVEC, INC.) 21 December 1995, see entire document, especially page 15.	1-39												
Y	MITANI et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl. Acad. Scie. USA. April 1995, Vol. 92, pages 3854-3858, especially pages 3854 and 3858.	1-39												
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*A* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 24 APRIL 1998		Date of mailing of the international search report 09 JUL 1998												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer DAVE NGUYEN Telephone No. (703) 308-0196												

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/03473

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GAGE et al. A Cell-Free Recombination System for Site-Specific Integration of Multigenic Shuttle Plasmids into the Herpes Simplex Virus Type 1 Genome. Journal of Virology. September 1992, Vol. 66, No. 9, pages 5509-5515, especially pages 5513-5514.	1-39
Y	ANTON et al. Site-Specific Recombination Mediated by an Adenovirus Vector Expressing the Cre Recombinase Protein: a Molecular Switch for Control of Gene Expression. Journal of Virology. August 1995, Vol. 69, No. 8, pages 4600-4606, especially page 4600.	1-39
Y	KANEGAE et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Research. 1995, Vol. 23, No. 19, pages 3816-3821, especially page 3816.	1-39
Y	DEUSCHLE et al. Tetracycline-Reversible Silencing of Eukaryotic Promoters. Molecular and Cellular Biology. April 1995, Vol. 15, No. 4, pages 1907-1914, especially page 1907.	1-39
Y	Database Medline on STN, AN 97098434, PARK et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal (Abstract). Proc. Natl. Acad. Sci. USA. 26 November 1996. Vol. 93, No. 24, pages 13565-13570, especially abstract.	1-39
Y	Database Medline on STN, AN 97083340, IMLER et al. Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors (abstract). Gene Therapy. January 1996, Vol. 3, No. 1, pages 75-84, especially abstract.	1-39